Abcellera Biologics Stock Analysis

Abcellera Stock Analysis Notes

About 23.0% of the company shares are held by company insiders. The company has price-to-book (P/B) ratio of 1.31. Some equities with similar Price to Book (P/B) outperform the market in the long run. Abcellera Biologics has Price/Earnings To Growth (PEG) ratio of 2.22. The entity recorded a loss per share of 0.64. The firm had not issued any dividends in recent years. AbCellera Biologics Inc. develops antibody discovery platform. The company was incorporated in 2012 and is headquartered in Vancouver, Canada. Abcellera Biologics is traded on NASDAQ Exchange in the United States. For more info on Abcellera Biologics please contact Carl Hansen at 604 559 9005 or go to https://www.abcellera.com.

Abcellera Biologics Investment Alerts

Abcellera Biologics Upcoming and Recent Events

Abcellera Largest EPS Surprises

View All Earnings Estimates

Abcellera Biologics Environmental, Social, and Governance (ESG) Scores

Abcellera Biologics Thematic Classifications

Abcellera Stock Institutional Investors

Note, although Abcellera Biologics' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Abcellera Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.34 B.

Abcellera Profitablity

Management Efficiency

Abcellera Biologics has return on total asset (ROA) of (0.1294) % which means that it has lost $0.1294 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.156) %, meaning that it created substantial loss on money invested by shareholders. Abcellera Biologics' management efficiency ratios could be used to measure how well Abcellera Biologics manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is expected to rise to -0.12 this year. Return On Capital Employed is expected to rise to -0.23 this year. At this time, Abcellera Biologics' Net Tangible Assets are quite stable compared to the past year. Non Currrent Assets Other is expected to rise to about 101.4 M this year, although the value of Non Current Assets Total will most likely fall to about 367.5 M.

Technical Drivers

As of the 19th of July, Abcellera Biologics shows the risk adjusted performance of 0.202, and Mean Deviation of 3.58. Abcellera Biologics technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices. Please confirm Abcellera Biologics jensen alpha, semi variance, and the relationship between the standard deviation and value at risk to decide if Abcellera Biologics is priced correctly, providing market reflects its regular price of 4.48 per share. Given that Abcellera Biologics has jensen alpha of 0.9622, we suggest you to validate Abcellera Biologics's prevailing market performance to make sure the company can sustain itself at a future point.

Abcellera Biologics Price Movement Analysis

Abcellera Biologics Insider Trading Activities

Abcellera Biologics Outstanding Bonds

Abcellera Biologics Predictive Daily Indicators

Abcellera Biologics Forecast Models

Abcellera Biologics' time-series forecasting models are one of many Abcellera Biologics' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Abcellera Biologics' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Abcellera Biologics prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Abcellera shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Abcellera Biologics. By using and applying Abcellera Stock analysis, traders can create a robust methodology for identifying Abcellera entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Abcellera analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Abcellera analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Abcellera Biologics stock analysis indicators help investors evaluate how Abcellera Biologics stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Abcellera Biologics shares will generate the highest return on investment. By understating and applying Abcellera Biologics stock analysis, traders can identify Abcellera Biologics position entry and exit signals to maximize returns.

Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Abcellera Biologics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For more information on how to buy Abcellera Stock please use our How to buy in Abcellera Stock guide.You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Abcellera Biologics. If investors know Abcellera will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Abcellera Biologics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Abcellera Biologics is measured differently than its book value, which is the value of Abcellera that is recorded on the company's balance sheet. Investors also form their own opinion of Abcellera Biologics' value that differs from its market value or its book value, called intrinsic value, which is Abcellera Biologics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Abcellera Biologics' market value can be influenced by many factors that don't directly affect Abcellera Biologics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Abcellera Biologics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Abcellera Biologics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Abcellera Biologics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.